We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+19.22%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$420M
AUM Growth
+$109M
(+35%)
Cap. Flow
+$13.8M
Cap. Flow
% of AUM
3.29%
Top 10 Holdings %
Top 10 Hldgs %
50.94%
Holding
96
New
34
Increased
16
Reduced
15
Closed
28
Avg Time Held Equity + Options
1.9
quarters
Top 10 Avg Time Held Equity + Options
1.9
quarters
Top 20 Avg Time Held Equity + Options
1.5
quarters
Avg Time Held Equity only
2.1
quarters
Top 10 Avg Time Held Equity only
1.9
quarters
Top 20 Avg Time Held Equity only
1.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$14.6M |
| 2 |
Gilead Sciences
GILD
|
+$12.1M |
| 3 |
GSK
GSK
|
+$9.11M |
| 4 |
Sanofi
SNY
|
+$8.01M |
| 5 |
Medtronic
MDT
|
+$7.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$18.6M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$8.58M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$7.52M |
| 4 |
Avantor
AVTR
|
+$6.99M |
| 5 |
InMode
INMD
|
+$5.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.32% |
| 2 | Miscellaneous | 21.55% |
| 3 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $66.8M | 15.91% |
+1,946,800
| New | +$23.4M |
2019 Q4
0 quarters
|
|
|
GWPH
2
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $19.4M | 4.63% |
185,757
+6,043
| +3% | +$678K |
2018 Q4
4 quarters
|
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $18.5M | 4.41% |
96,931
-3,698
| -4% | -$667K |
2019 Q3
1 quarter
|
|
4
Coherus Oncology
CHRS
$165M
| $17M | 4.06% |
946,761
+341,976
| +57% | +$6.31M |
2019 Q2
2 quarters
|
|
|
5
Medtronic
MDT
$119B
| $16.7M | 3.97% |
147,022
+66,320
| +82% | +$7.28M |
2018 Q3
5 quarters
|
|
6
HCA Healthcare
HCA
$99.8B
| $16.2M | 3.86% |
109,599
-25,000
| -19% | -$3.36M |
2018 Q1
7 quarters
|
|
|
7
Merck
MRK
$350B
| $15.4M | 3.68% |
+177,903
| New | +$14.6M |
2019 Q4
0 quarters
|
|
8
Pfizer
PFE
$162B
| $14.9M | 3.55% |
401,441
+99,523
| +33% | +$3.54M |
2019 Q3
1 quarter
|
|
|
WCG
9
DELISTED
Wellcare Health Plans, Inc.
WCG
| $14.8M | 3.53% |
44,935
-5,500
| -11% | -$1.65M |
2019 Q1
3 quarters
|
|
10
PUT
CEL-SCI Corp
CVM
$30.8M
| $14M | 3.33% |
50,920
+27,733
| +120% | +$6.54M |
2019 Q3
1 quarter
|
|
|
11
Gilead Sciences
GILD
$183B
| $12.1M | 2.88% |
+186,000
| New | +$12.1M |
2019 Q4
0 quarters
|
|
12
United Therapeutics
UTHR
$23.3B
| $11.7M | 2.78% |
132,664
+45,000
| +51% | +$3.96M |
2018 Q4
4 quarters
|
|
13
Molina Healthcare
MOH
$10.9B
| $9.94M | 2.37% |
73,236
+40,746
| +125% | +$5.13M |
2018 Q4
4 quarters
|
|
|
14
GSK
GSK
$92.7B
| $9.62M | 2.29% |
+163,764
| New | +$9.11M |
2019 Q4
0 quarters
|
|
15
McKesson
MCK
$112B
| $9.47M | 2.25% |
68,439
+5,249
| +8% | +$742K |
2019 Q3
1 quarter
|
|
16
Cencora
COR
$63B
| $9.46M | 2.25% |
111,249
+8,146
| +8% | +$698K |
2019 Q3
1 quarter
|
|
17
Regeneron Pharmaceuticals
REGN
$77.5B
| $9.3M | 2.22% |
24,776
| – | – |
2019 Q3
1 quarter
|
|
18
Elevance Health
ELV
$92.2B
| $9.28M | 2.21% |
30,739
+3,454
| +13% | +$950K |
2019 Q2
2 quarters
|
|
|
19
Sanofi
SNY
$93.7B
| $8.58M | 2.04% |
+170,977
| New | +$8.01M |
2019 Q4
0 quarters
|
|
20
DELISTED
BioTelemetry, Inc.
BEAT
| $7.41M | 1.76% |
160,015
-31,025
| -16% | -$1.34M |
2019 Q2
2 quarters
|
|
21
Lite Strategy Inc
LITS
$36.8M
| $5.95M | 1.42% |
119,943
+107,000
| +827% | +$3.98M |
2017 Q4
8 quarters
|
|
22
Viking Therapeutics
VKTX
$3.39B
| $5.87M | 1.4% |
731,453
-23,306
| -3% | -$170K |
2017 Q4
8 quarters
|
|
23
Immunovant
IMVT
$5.93B
| $5.48M | 1.31% |
+615,400
| New | +$6.89M |
2019 Q4
0 quarters
|
|
24
Merit Medical Systems
MMSI
$5.26B
| $4.68M | 1.12% |
+150,000
| New | +$4.3M |
2019 Q4
0 quarters
|
|
25
Ardelyx
ARDX
$806M
| $4.67M | 1.11% |
+621,534
| New | +$3.78M |
2019 Q4
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Sio Capital Management held 96 positions worth $420M, up 35% from $310M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Sio Capital Management deployed $13.8M of net new capital in Q4 2019, opening 34 new positions and adding to 16 existing holdings. Its largest new stake was Merck: 177,903 shares worth $15.4M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $8.58M trimmed.
- Sio Capital Management's largest Q4 2019 buy was Merck: 177,903 shares worth $15.4M.
- Sio Capital Management added most to Medtronic in Q4 2019, an estimated $7.28M increase.
- Sio Capital Management's biggest Q4 2019 reduction was Alnylam Pharmaceuticals, cutting an estimated $8.58M.
- Sio Capital Management fully exited Johnson & Johnson in Q4 2019, selling an estimated $18.6M.
- Sio Capital Management's ten largest holdings make up 51% of its $420M portfolio in Q4 2019.
- Sio Capital Management opened 34 new positions and closed 28 in Q4 2019.
- Sio Capital Management's portfolio value rose 35% quarter-over-quarter to $420M.
Based on Sio Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.